CLIA Kit for Matrix Metalloproteinase 10 (MMP10) Sus scrofa; Porcine (Pig) Sandwich CLIA

STMY2; SL2; Stromelysin 2; Transin-2

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Matrix Metalloproteinase 10 (MMP10) Packages (Simulation)
  • CLIA Kit for Matrix Metalloproteinase 10 (MMP10) Packages (Simulation)
  • CLIA Kit for Matrix Metalloproteinase 10 (MMP10) Results demonstration
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Matrix Metalloproteinase 10 (MMP10) and the recovery rates were calculated by comparing the measured value to the expected amount of Matrix Metalloproteinase 10 (MMP10) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 96-105 102
EDTA plasma(n=5) 78-105 101
heparin plasma(n=5) 79-102 98

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Matrix Metalloproteinase 10 (MMP10) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Matrix Metalloproteinase 10 (MMP10) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Matrix Metalloproteinase 10 (MMP10) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 93-101% 96-105% 93-105% 81-101%
EDTA plasma(n=5) 90-98% 82-92% 86-103% 96-103%
heparin plasma(n=5) 87-103% 95-103% 95-104% 86-97%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Matrix Metalloproteinase 10 (MMP10)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Matrix Metalloproteinase 10 (MMP10). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Matrix Metalloproteinase 10 (MMP10). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Matrix Metalloproteinase 10 (MMP10) level in the sample or standard.;

Citations

  • Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodellingWiley: source
  • Matrix Metalloproteinase-10 Is Required for Lung Cancer Stem Cell Maintenance, Tumor Initiation and Metastatic PotentialPubMed: PMC3335833
  • A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic ApproachesPlosone: Source
  • Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic strokePubmed:24671655
  • Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model Pubmed:25266150
  • In vivo bioengineered ovarian tumors based on collagen, matrigel, alginate and agarose hydrogels: a comparative studyPubmed:25634132
  • Plasma inflammatory biomarkers for Huntington’s disease patients and mouse modelPubMed: 25266150

Recommend products